---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-078719"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-07-06T23:59:59+00:00"
generated_at: "2026-06-13T12:14:52.157977+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics enters three facility leases in Shanghai and South San Francisco

## Summary
- Operations lease for ~22,500 sq ft in Shanghai; annual rent ~5.20M yuan (~$0.72M); term Jan 2024–Dec 2026.
- Lab lease for ~8,400 sq ft in Shanghai; annual rent ~1.99M–2.12M yuan (~$0.27–0.29M); term Feb 2024–Jan 2027.
- Sublease for ~11,800 sq ft in South San Francisco; annual rent ~$0.49M initial +3% annual; term Aug 2023–Aug 2027, with 4-month rent abatement.
- Leases support R&D operations in China and corporate headquarters in the US.

## SEC filing metadata
- accession: 0001104659-23-078719
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-07-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/tm2319105d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-078719
- JSON: https://secwatch.observer/filing/0001104659-23-078719.json
- Plain text: https://secwatch.observer/filing/0001104659-23-078719.txt

## Key facts
- Material Agreements
  Structure Therapeutics Inc. entered into Sublease with Aligos Therapeutics, Inc. valued at approximately US$0.49 million (effective 2023-06-29).
  - Action: entry
  - Agreement: lease
  - Counterparty: Aligos Therapeutics, Inc.
  - Value: approximately US$0.49 million
  - Effective: 2023-06-29
  source text: On June 29, 2023, Structure Therapeutics USA Inc., the Company’s wholly owned subsidiary (“Structure USA”) entered into a sublease agreement (the “Sublease”) with Aligos Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm
- Material Agreements
  Structure Therapeutics Inc. entered into Lab Lease with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd. valued at approximately 1.99 million yuan, or approximately US$0.27 million (effective 2023-06-29).
  - Action: entry
  - Agreement: lease
  - Counterparty: Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd.
  - Value: approximately 1.99 million yuan, or approximately US$0.27 million
  - Effective: 2023-06-29
  source text: On June 29, 2023, Shanghai ShouTi, entered into a lease agreement (the “Lab Lease”) with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm
- Material Agreements
  Structure Therapeutics Inc. entered into Operations Lease with Shanghai Changtai Business Management Co., Ltd. valued at approximately 5.20 million yuan, or approximately US$0.72 million (effective 2023-06-29).
  - Action: entry
  - Agreement: lease
  - Counterparty: Shanghai Changtai Business Management Co., Ltd.
  - Value: approximately 5.20 million yuan, or approximately US$0.72 million
  - Effective: 2023-06-29
  source text: On June 29, 2023, Shanghai ShouTi Biotechnology Co., Ltd., the Company’s wholly owned subsidiary. (“Shanghai ShouTi”) entered into a lease agreement (the “Operations Lease”) with Shanghai Changtai Business Management Co., Ltd.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.